EULAR 2025: Five strategic signals shaping the future of immunology
EULAR 2025 underscored a pivotal inflection point in immunology, revealing critical shifts across therapy development, clinical strategy, and commercial positioning. From the rise of next-generation oral agents to the emergence of curative modalities, the immunology pipeline is growing more dynamic, diverse, and competitive. This brief outlines five key strategic signals that emerged from the congress, each shaping the next decade of innovation and investment in autoimmune and inflammatory diseases.
1. TYK2 inhibition redefines the PsA treatment paradigm
Bristol Myers Squibb’s Sotyktu (deucravacitinib) took center stage with Phase 3 data from POETYK PsA-1 and PsA-2 trials. The oral, selective TYK2 inhibitor achieved ACR20 responses exceeding 54% at Week 16, significantly outperforming placebo while maintaining a clean safety profile.
Implication: TYK2 inhibitors offer a more targeted, safer alternative to JAKs, avoiding black box warnings while delivering robust efficacy. Sotyktu’s expansion into psoriatic arthritis from psoriasis marks the evolution of selective cytokine modulation as a cornerstone strategy.
2. Multi-indication expansion becomes a core commercial strategy
The “pipeline-in-a-product” model continues to gain traction. Assets like Tremfya (guselkumab), Rinvoq (upadacitinib), and Sotyktu exemplify how companies are designing therapies for use across rheumatology, dermatology, and gastroenterology.
At EULAR, Tremfya’s new PsA data reaffirmed its cross-specialty utility. These therapies are not only clinically validated across diseases but also optimized for portfolio continuity and lifecycle transitions (e.g., Stelara to Tremfya, Humira to Rinvoq).
Implication: Multi-indication strategies drive R&D efficiency, patient retention, and commercial durability. Expect growing regulatory alignment and payer evaluation of assets through a cross-disease lens.
3. Novel mechanisms push the innovation frontier
Several first-in-class agents showcased potential in hard-to-treat conditions:
- Enpatoran (Merck KGaA): A TLR7/8 inhibitor showed strong Phase 2 results in lupus, targeting upstream innate immune signaling.
- CPL’116 (Celon Pharma): Combines JAK1/3 and ROCK inhibition, showing rapid RA response by Week 12.
These agents offer differentiated mechanisms with more precise immune modulation and could open new chapters in diseases where conventional agents fall short.
Implication: Mechanistic novelty is back in focus. Despite higher clinical risk, these assets hold outsized value in areas of high unmet need, especially in lupus, refractory RA, and rare autoimmune subsets.
4. Cell and gene therapies signal a remission-oriented future
In a groundbreaking shift, CAR-T therapies entered the autoimmune spotlight:
- Resecabtagene autoleucel (rese-cel, Cabaletta Bio) induced drug-free remission in lupus and myositis.
- FT819 (Fate Therapeutics), an off-the-shelf CD19 CAR-T, debuted early data in SLE.
These programs mark the transition from chronic immunosuppression to one-time, potentially curative therapies, echoing the transformational trajectory seen in oncology.
Implication: Autoimmune cell therapies are no longer theoretical. They bring new questions around pricing, access, and care delivery — but also the potential to redefine disease management and payer value models.
5. The future is indication-agnostic and mechanism-centric
EULAR 2025 highlighted a deepening convergence in how autoimmune diseases are viewed and treated. Shared immune pathways enable the application of one therapy across multiple diseases, while innovative agents increasingly target core immunologic mechanisms rather than disease-specific phenotypes.
Sotyktu’s journey from psoriasis to PsA and onward to SLE illustrates this trend, as do the multi-disease ambitions of CAR-T platforms and next-gen inhibitors.
Implication: The next competitive frontier in immunology lies in mastering both breadth (multi-indication use) and depth (mechanistic innovation). Companies must invest in platform thinking — clinically, commercially, and operationally.
Conclusion: A dual mandate for future success
To lead in immunology’s next decade, companies must embrace a dual mandate:
- Extend the reach of validated assets across indications
- Invest early in high-risk, high-reward innovations that could reset standards of care
EULAR 2025 offered a glimpse into evolution of immunology field: towards more targeted, versatile, and transformative therapies. For pharma leaders, the message is clear: those who combine strategic scale with scientific boldness will shape the next era of autoimmune care.
